{"filings":[{"id":695519,"accession_number":"0001193125-26-241867","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2026-05-27T20:05:16+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Aptevo (APVO) partners with Niowave for radiopharma development; Niowave takes 7.9% equity stake","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs using Aptevo's multispecific platforms and Niowave's radioisotopes.","Niowave made initial $500K equity investment for 7.9% stake; potential up to 19.99% through warrant exercises at $8.00/share.","First program targets Nectin-4 with Actinium-225; proof-of-concept study to begin.","Deal marks Aptevo's expansion into radiopharmaceuticals; Niowave's first therapeutic development investment.","Niowave to supply radioisotopes if it opts out of collaboration; Aptevo retains development rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68016,"accession_number":"0001193125-26-221593","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2026-05-13T20:05:18+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aptevo reports 81% remission rate for mipletamig in frontline AML; $60M equity line secured","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mipletamig plus venetoclax/azacitidine: 87% clinical benefit rate, 81% CR/CRi, 65% CR in 31 evaluable patients; no CRS.","RAINIER trial on track for completion and Phase 2 dose selection by year-end 2026.","Q1 2026 cash position $14.5M; raised $0.9M net under SEPAs; secured new $60M SEPA with Yorkville.","Jeff Lamothe appointed CEO; Marvin White transitions to Executive Chair.","Leadership believes the $60M facility extends capital access into 2029 through key catalysts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94561,"accession_number":"0001193125-26-208958","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aptevo Reports 87% Clinical Benefit Rate and 81% Remission in Frontline AML Trial RAINIER","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Across 31 evaluable frontline AML patients, mipletamig combo showed 87% clinical benefit rate and 81% remission (CR/CRi), outperforming VIALE-A benchmark of 66.4%.","Phase 1b dose optimization trial on track for 2026 completion; final cohorts 6 and 7 under enrollment with Cohort 6 nearing completion.","65% achieved complete remission vs 37% historical benchmark; 52% of remissions were MRD-negative.","No cytokine release syndrome reported; 6 patients proceeded to allogeneic stem cell transplant.","Phase 2 dose selection and regulatory interaction planned after dataset completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107040,"accession_number":"0001193125-26-126190","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aptevo FY2025 net loss $26M, cash $21.6M; mipletamig 86% CBR in AML; CEO transition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Mipletamig triplet in 28 frontline AML patients: 86% CBR, 79% CR/CRi, no CRS observed.","Expanded CD3 pipeline with three new candidates including first trispecific assets.","Established $60M equity line with Yorkville; supports operations potentially into 2029.","Cash $21.6M at Dec 31, 2025 (up from $8.7M); net loss $26.0M vs $24.1M in 2024.","CEO Marvin White becomes Executive Chair; Jeff Lamothe named President and CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107039,"accession_number":"0001193125-26-100539","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aptevo reports 86% clinical benefit rate for mipletamig combo in frontline AML, zero CRS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mipletamig + venetoclax + azacitidine showed 86% clinical benefit rate (CR/CRi/PR) in 28 evaluable frontline AML patients.","79% achieved CR or CRi; 61% achieved CR; 55% of CR/CRi patients reached MRD-negative status.","No cytokine release syndrome (CRS) observed; 35% of responders had high-risk TP53 mutation.","Four patients proceeded to allogeneic stem cell transplant, a rare outcome in older/unfit patients.","Data from RAINIER Phase 1b/2 trial and completed dose expansion trial support safety and tolerability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107038,"accession_number":"0001193125-26-057707","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aptevo shareholders approve issuance of >19.99% of common stock to Yorkville","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved issuance of more than 19.99% of outstanding common stock under Standby Equity Purchase Agreement with Yorkville.","Vote on Proposal 2 (stock issuance): 83,051 for, 29,168 against, 1,816 abstain, 225,099 broker non-votes.","Proposal 1 (charter amendment for technical changes) not approved: 273,162 for, 61,044 against, 4,928 abstain.","Proposal 3 (adjournment) approved: 270,356 for, 64,975 against, 3,803 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.15,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107037,"accession_number":"0001193125-26-034473","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Marvin White retires as Aptevo CEO; COO Jeff Lamothe named successor effective April 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["White to become Executive Chair; Lamothe promoted from COO to President and CEO and appointed to Board.","John Niederhuber transitions from Chairman to Lead Independent Director; Board expands to seven directors.","Lamothe receives $650K base salary, 60% bonus target, and a one-time $150K cash promotional award.","Severance Plan modified to align Executive Chair benefits with CEO-level benefits; EVP tier removed.","Company notes cash runway into 2029, $60M equity line, and clinical progress with mipletamig Phase 1b."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107036,"accession_number":"0001193125-26-008318","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Aptevo secures $60M equity line with Yorkville, extends funding runway into 2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enters $60M Standby Equity Purchase Agreement with Yorkville; minimal fees, no warrants.","Company has right to sell shares at 96% of lowest 3-day VWAP; capped at ~199,466 shares without approval.","Fully leveraged facility plus cash on hand expected to extend funding into 2029.","Proceeds to support pipeline including mipletamig (CD123xCD3) in Phase 1b/2 frontline AML trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123380,"accession_number":"0001193125-25-335497","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Aptevo Therapeutics files 1-for-18 reverse stock split effective Dec 29, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse split ratio 1-for-18 approved by board Dec 17; effective Dec 29 at 5:01 PM ET.","Split-adjusted trading on Nasdaq begins Dec 30; new CUSIP 03835L702.","No fractional shares issued; cash in lieu; adjustments to options, warrants, RSUs.","Stockholders approved split on July 24, 2025 Special Meeting; range 1:6–1:22.","Forward-looking statements acknowledge risk of ability to continue as going concern."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123379,"accession_number":"0001193125-25-312972","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aptevo reports mipletamig 93% ORR, zero CRS in frontline AML Phase 1b/2 trial at ASH 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% of patients free of cytokine release syndrome (CRS) across cohorts 1-3.","93% overall response rate (ORR) among evaluable patients; 87% CR/CRi, 73% CR.","60% of MRD-evaluable CR/CRi patients achieved MRD-negative status; 43% of ORR patients had TP53 mutation.","Median patient age 75; triplet regimen (mipletamig + AZA/VEN) generally well tolerated.","Data presented Dec 8 at ASH 2025; RAINIER trial continues enrollment at additional dose levels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123378,"accession_number":"0001193125-25-269470","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aptevo reports 89% remission in frontline AML with mipletamig; Q3 net loss $7.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["89% of evaluable frontline AML patients achieved remission (CR+CRi) across two trials of mipletamig; no cytokine release syndrome observed.","Introduced trispecific molecules APVO451 and APVO452 for solid tumors, expanding CD3 T-cell engager portfolio to five candidates.","Raised $18.7M net in Q3 and additional $4.1M in October; proforma cash $25.2M extends runway into 4Q26.","Q3 net loss $7.5M ($2.23 per share) vs $5.1M ($357.86 per share) in Q3 2024; R&D spend $4.0M, G&A $3.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-11.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123377,"accession_number":"0001193125-25-258665","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["1.01","3.03","9.01"],"status":"ready","headline":"Aptevo extends shareholder rights agreement Final Expiration Date to Oct 29, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 5 to Rights Agreement extends Final Expiration Date from Nov 2025 to Oct 29, 2026.","Rights originally adopted Nov 8, 2020; no other terms of the agreement were changed.","Extension covers contingent rights to purchase 1/1000th of Series A Junior Participating Preferred Stock.","Broadridge Corporate Issuer Solutions remains rights agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140041,"accession_number":"0001193125-25-205107","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aptevo reports 100% remission rate in Cohort 3 of Phase 1b/2 RAINIER trial for mipletamig in AML","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% remission rate (CR/CRi) in Cohort 3 with mipletamig + venetoclax + azacitidine for newly diagnosed AML unfit for intensive chemo.","No dose-limiting toxicities or cytokine release syndrome observed across all RAINIER cohorts; safety profile clean.","40% of treated patients achieved minimal residual disease (MRD)-negative status, a marker associated with improved outcomes.","Cohort 4 now enrolling at next dose level; data expected at major medical conference in Q4 2025.","Frontline AML market is multibillion-dollar; mipletamig could redefine standard of care if later-stage data confirm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140040,"accession_number":"0001671584-25-000005","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aptevo expands oncology pipeline with two new trispecific candidates APVO452 and APVO451","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed provisional patents for APVO452 (PSMA x CD3 x CD40) targeting prostate cancer and APVO451 (Nectin-4 x CD3 x CD40) for multiple solid tumors.","Trispecific design engages tumor antigen, T cells, and immunosuppressive cells via ADAPTIR-FLEX platform to modulate tumor microenvironment.","Mipletamig clinical validation: >100 patients treated with high remission rates and no observed cytokine release syndrome in frontline AML.","Pipeline now includes 8 bispecific/trispecific candidates; 5 employ CRIS-7-derived CD3 binding domain for improved safety."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140039,"accession_number":"0000950170-25-106246","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aptevo Q2 net loss $6.2M; mipletamig 85% remission in AML; pipeline expands with APVO455","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.2M for Q2 2025; cash $9.4M as of June 30, 2025.","Raised $15.9M in Q2; extended cash runway into late Q4 2025; secured up to $25M equity line.","Introduced APVO455, a Nectin-4 x CD3 bispecific for bladder, breast, NSCLC, head & neck cancers.","Mipletamig achieved 85% remission rate (11/13) in frontline AML; no CRS reported.","Shares outstanding grew to 3,224,156 vs 72,922 at Dec 31, 2024 due to equity raises."],"consensus_eps_estimate":-1527.552,"consensus_eps_actual":-30.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140038,"accession_number":"0000950170-25-098429","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aptevo shareholders approve reverse stock split and Yorkville equity issuance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected directors Marvin L. White (443,945 for) and John E. Niederhuber (444,661 for) to board.","Approved reverse stock split at ratio 1:6 to 1:20, board to set timing and exact ratio.","Approved issuance of >19.99% of outstanding shares under SEPA with YA II PN, Ltd. (Yorkville).","Approved Third Amended and Restated 2018 Stock Incentive Plan and non-binding advisory say-on-pay.","Ratified Baker Tilly as independent auditor for fiscal 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140037,"accession_number":"0000950170-25-092318","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aptevo regains Nasdaq compliance with $15.9M equity raise","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice confirming compliance with minimum $2.5M stockholders' equity rule.","Raised ~$15.9M gross proceeds from equity capital in quarter ended June 30, 2025.","Company previously disclosed non-compliance for quarter ended March 31, 2025.","Believes stockholders' equity now exceeds $2.5M threshold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157684,"accession_number":"0000950170-25-091581","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aptevo raises $15.9M in Q2 equity offerings, believes it regains Nasdaq compliance on stockholders' equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised approx. $15.9M via four equity transactions: April 4 ($2.1M), April 22 ($2.0M), June 20 ($8.0M), and ATM facility ($3.8M).","Company believes stockholders' equity now exceeds the $2.5M minimum required by Nasdaq Listing Rule 5550(b)(1).","Awaiting formal confirmation from Nasdaq of compliance; previously disclosed deficiency for quarter ended March 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157683,"accession_number":"0000950170-25-088970","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Aptevo Therapeutics appoints Baker Tilly as new auditor after Moss Adams merger","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Moss Adams merged with Baker Tilly effective June 3, 2025; Moss Adams resigned and Baker Tilly appointed for FY2025.","No disagreements or reportable events with Moss Adams during 2024/2023 and subsequent interim period.","Prior audit reports from Moss Adams included a going concern uncertainty explanatory paragraph."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157682,"accession_number":"0000950170-25-088592","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Aptevo files prospectus supplement for ATM offering of up to $8.0M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement for ATM offering of up to $8,037,381 in common stock via Roth Capital Partners.","As of June 20, had sold 481,828 shares for gross proceeds of $3,765,143 under the April 2025 Sales Agreement.","Offering is registered under Form S-3 (File No. 333-284969); legal opinion from Paul Hastings LLP filed as exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157681,"accession_number":"0000950170-25-088494","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Aptevo raises $8M, reports 85% remission for mipletamig in AML, adds APVO455","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$8M from registered direct offering of 2.465M shares/pre-funded warrants and 12.325M common warrants at $3.25/unit.","Net proceeds ~$7.45M; funds for clinical development, working capital, and general corporate purposes.","Mipletamig (CD123xCD3) shows 85% remission rate in evaluable frontline AML patients in RAINIER trial; no CRS in first two cohorts.","Cohort 3 nears full enrollment at highest dose; mipletamig triplet therapy enables transplant in previously ineligible patient.","New preclinical candidate APVO455 (Nectin-4xCD3) added to CD3-targeted pipeline using CRIS-7 domain; targets solid tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157680,"accession_number":"0000950170-25-087368","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Aptevo Therapeutics enters $25M standby equity purchase agreement with Yorkville","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $25M in common stock may be sold to YA II PN over 36 months at 96% of lowest 3-day VWAP.","Exchange cap of 151,755 shares (19.99% of outstanding) unless stockholder approval or avg price ≥ $3.66.","Yorkville's beneficial ownership limited to 9.99% of outstanding shares.","Structuring fee of $25,000 paid; commitment fee of 2% of commitment amount in five quarterly installments.","Advance subject to filing and effectiveness of registration statement with the SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157679,"accession_number":"0000950170-25-077089","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Aptevo Therapeutics effects 1-for-20 reverse stock split effective May 23, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse split 1:6 to 1:20 at May 14 special meeting; board chose 1:20 on May 21.","Filed Certificate of Amendment effective 5:01 PM ET May 23; shares trade split-adjusted from May 27.","No fractional shares issued; cash payment in lieu for stockholders; warrants rounded up to whole share.","New CUSIP 03835L 504; par value remains $0.001 per share; adjustments to options, RSUs, warrants.","Reverse split reduces outstanding shares proportionately, no change in percentage ownership for stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157678,"accession_number":"0000950170-25-076482","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Aptevo receives Nasdaq delisting notice for equity deficiency; announces 1-for-20 reverse split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Aptevo of non-compliance with $2.5M stockholders' equity rule; deficit of $1.473M as of March 31, 2025.","Company has 45 days (by July 7, 2025) to submit compliance plan; if accepted, until Nov 18, 2025 to regain compliance.","Announces 1-for-20 reverse stock split effective May 23, 2025; shares begin trading split-adjusted May 27.","Files prospectus supplement for up to $3.015M of common stock under ATM with Roth Capital.","Outstanding shares to reduce from ~13.5M to ~0.7M; no change to ticker APVO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157677,"accession_number":"0000950170-25-072594","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aptevo reports 90% remission rate in frontline AML with mipletamig triplet; no CRS","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["9 of 10 frontline AML patients achieved remission with mipletamig + venetoclax + azacitidine across two trials.","RAINIER Cohort 2 fully enrolled; Cohort 3 now open; 5/6 patients in Cohort 1 achieved remission within 30 days.","No cytokine release syndrome observed in ongoing RAINIER trial; favorable safety profile attributed to ADAPTIR format.","Financial results for Q1 2025 reported but no specific figures disclosed in this release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157676,"accession_number":"0000950170-25-060317","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aptevo files prospectus supplement to sell up to $3.17M in common stock via ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM offering of up to $3,167,548 in common stock under sales agreement with Roth Capital Partners.","As of April 29, 2025, 305,845 shares sold at $0.5946/share for $181,848 gross proceeds.","Supplement amends prior April 28, 2025 prospectus supplement; legal opinion filed as Exhibit 5.1.","Shares offered under existing S-3 registration statement (File No. 333-284969).","Paul Hastings LLP provided the legal opinion included in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157675,"accession_number":"0000950170-25-058966","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["1.01","2.02","8.01","9.01"],"status":"ready","headline":"Aptevo enters ATM equity facility up to $2.96M; reports preliminary Q1 cash of $2.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered ATM sales agreement with Roth Capital to sell up to $2,959,952 in common stock; Roth receives 3.0% commission.","Preliminary cash and equivalents as of March 31, 2025: $2.1M (unaudited, subject to change).","Subsequent registered direct offerings on April 4 and April 22 raised approx. $1.9M and $1.8M respectively.","Company has not finalized Q1 2025 financial results; independent auditor has not reviewed preliminary data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157674,"accession_number":"0000950170-25-056736","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Aptevo raises $2.0M in registered direct offering at $0.862/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 2,324,000 shares at $0.862 each, gross proceeds ~$2.0M; net ~$1.8M after fees.","Roth Capital Partners acted as exclusive placement agent, receiving 7.0% cash fee.","Proceeds to fund clinical programs, working capital, and general corporate purposes.","Offering closed April 22, 2025; 5-day lockup on further equity issuance following close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157673,"accession_number":"0000950170-25-051143","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Aptevo raises $2.1M in registered direct offering and private placement; existing warrants amended","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,764,710 shares of common stock and warrants to purchase up to 3,529,420 shares at $1.19/unit.","Gross proceeds ~$2.1M; net proceeds ~$1.9M after fees; Roth Capital acted as placement agent.","Amended existing Dec 2024 warrants: exercise price reduced from $9.53 to $1.19 per share.","Exercise of new and amended warrants requires stockholder approval; warrants expire 5 years from approval date.","Proceeds for clinical development of product candidates and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176056,"accession_number":"0000950170-25-042340","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Two additional AML patients achieve remission in Cohort 2 of RAINIER trial; 90% response rate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two additional AML patients in Cohort 2 of RAINIER trial achieved remission within 30 days of treatment.","Overall 9 of 10 frontline AML patients achieved remission with mipletamig + ven/aza triplet, vs 66% doublet benchmark.","Complete remission rate (CR) of 70% with triplet outperforms 36% CR from Viale-A ven/aza only study.","No cytokine release syndrome (CRS) observed in RAINIER trial to date; all remissions ongoing.","Cohort 2 enrollment nearing completion; six patients planned at 18 mcg dose level."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176055,"accession_number":"0000950170-25-020465","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aptevo reports 100% remission in Cohort 1 of RAINIER AML trial; 59% stable disease rate in ALG.APV-527 trial","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Mipletamig RAINIER Cohort 1: 100% of patients achieved remission within 30 days, including one MRD-negative status.","ALG.APV-527 Phase 1: 59% (10/17 evaluable) stable disease rate; breast cancer patient stable >12 months.","Company expects multiple data readouts in 2025 and will present at ASH in Q4 2025.","No specific financial results for FY 2024 are disclosed in the provided exhibit text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176054,"accession_number":"0000950170-25-017473","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aptevo Therapeutics provides pipeline update via investor presentation","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Presentation highlights clinical candidates mipletamig and ALG.APV-527.","Preclinical candidates APVO711, APVO603, APVO442 are also detailed.","No new clinical data, trial results, or financial guidance provided.","Presentation dated February 11, 2025, furnished under Regulation FD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192973,"accession_number":"0000950170-24-135890","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Aptevo raises up to $6.2M via warrant exercise inducement; issues new warrants at $9.53","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders exercise up to 823,544 existing warrants at $7.50/share for ~$6.2M gross proceeds.","Company issues new warrants to buy 200% of shares exercised at $9.53, 5-year term.","Roth Capital gets 7% advisory fee; proceeds used for working capital.","Resale registration statement for new warrant shares due by Dec. 27, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192972,"accession_number":"0000950170-24-135609","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aptevo: 100% remission in Cohort 1 of mipletamig frontline AML trial; 2 of 3 patients MRD-negative","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% of patients (3/3) achieved remission within 30 days in Cohort 1 of RAINIER Phase 1b trial.","Two patients achieved complete remission with MRD-negative status, including one with TP53 mutation.","Results build on prior trial where 100% of frontline patients also achieved remission.","Mipletamig continues to show favorable safety and tolerability profile; Cohort 2 enrollment commencing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192971,"accession_number":"0000950170-24-133091","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aptevo unveils preclinical bispecific APVO442 for prostate cancer; targets $14B market","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["APVO442 is a PSMA x CD3 bispecific antibody designed to treat prostate cancer.","First molecule developed using Aptevo's ADAPTIR-FLEX platform.","Prostate cancer market valued at ~$14B, expected to grow to $24B+ over ten years.","Preclinical studies show tumor localization and reduced binding to circulating immune cells.","Aims to address advanced-stage prostate cancer with improved safety and efficacy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192970,"accession_number":"0000950170-24-132855","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Aptevo Therapeutics completes 1-for-37 reverse stock split effective December 3, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Certificate of Amendment filed with Delaware; split effective at 5:01 p.m. ET on December 3, 2024.","Every 37 pre-split shares combined into one share; par value unchanged; no fractional shares issued.","Trading on Nasdaq Capital Market begins on split-adjusted basis December 4, 2024; new CUSIP 03835L 405.","Proportionate adjustments made to stock options, RSUs, warrants, and equity plan reserves.","Stockholders' percentage ownership unchanged except for fractional share cash payments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192969,"accession_number":"0000950170-24-130763","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aptevo's Peter Pavlik to present ADAPTIR platform at Pep Talk; new molecule expected in early 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Peter Pavlik, PhD, will chair a 'Bi and Multispecific Biologics' session at Pep Talk conference in January 2025.","Presentation will highlight ADAPTIR platform using clinical candidates Mipletamig and ALG.APV-527 as proof of concept.","Aptevo has five compounds in clinical/preclinical development and plans a new molecule in early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192968,"accession_number":"0000950170-24-129971","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aptevo highlights bispecific pipeline; first AML patient shows 90% blast reduction","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["First patient in Phase 1b/2 RAINIER trial for mipletamig achieved 90% leukemic blast reduction within 30 days.","ALG.APV-527 Phase 1 data: 9 of 16 evaluable patients (56%) achieved stable disease; safety and tolerability positive.","Preclinical candidates APVO711, APVO603, APVO442 target PD-L1/CD40, 4-1BB/OX40, PSMA/CD3 respectively.","Company plans to add another targeted asset to pipeline in near-term but provides no details.","No financial updates or guidance provided; no leadership or corporate changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192967,"accession_number":"0000950170-24-129018","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aptevo reports first RAINIER trial patient achieved 90% leukemic blast reduction in 30 days","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient in Phase 1b/2 RAINIER trial achieved 90% reduction in leukemic blasts within first 30 days.","Mipletamig (CD3 x CD123 bispecific) evaluated as frontline therapy in combination with venetoclax and azacitidine for AML.","Data builds on prior studies showing strong safety profile with manageable CRS below comparable treatment modalities.","RAINIER is designed for statistically defined efficacy analysis in newly diagnosed patients with limited options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192966,"accession_number":"0000950170-24-122830","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aptevo Q3 net loss $5.1M; cash $7.8M; initiates RAINIER trial for AML","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.1M ($0.48 per share) in Q3 2024 vs $6.3M ($22.16) in Q3 2023.","Cash and cash equivalents $7.8M as of Sept 30, 2024, down from $16.9M at Dec 31, 2023.","Initiated Phase 1b/2 RAINIER trial for mipletamig in frontline AML based on positive dose escalation data.","ALG.APV-527 Phase 1 data: 60% of evaluable patients (9/15) achieved stable disease as monotherapy.","Raised $5.75M in two financings during the quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192965,"accession_number":"0000950170-24-120188","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["1.01","3.03","9.01"],"status":"ready","headline":"Aptevo Therapeutics extends poison pill expiration to Oct 2025, adjusts purchase price to $70","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Amendment No. 4 extends Rights Agreement Final Expiration Date to October 31, 2025.","Purchase Price changed to $70 per one one-thousandth of a Series A Preferred Share.","Rights Agreement originally dated November 8, 2020; Amendment modified rights of security holders.","Entered into with Broadridge Corporate Issuer Solutions as Rights Agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192964,"accession_number":"0000950170-24-117439","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aptevo shareholders approve reverse stock split (1:5–1:37) and dilutive stock issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stock issuance and warrant proposal passed (593,301 For, 412,901 Against, 5,355 Abstain).","Reverse stock split approved at ratio of 1-for-5 to 1-for-37; board sets timing and exact ratio.","Adjournment proposal also approved (2,017,270 For, 1,253,171 Against, 9,145 Abstain).","Issuance covers >19.99% of outstanding common stock with price adjustment warrants per Sept 16 agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209342,"accession_number":"0000950170-24-107776","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Aptevo raises $3.0M via registered direct offering of stock and warrants at $0.33/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 9,090,910 shares or pre-funded warrants plus warrants for up to 18,181,820 shares at $0.33 per unit.","Gross proceeds ~$3.0M; net proceeds ~$2.5M after fees; proceeds for clinical development and working capital.","Existing warrants covering 11,822,774 shares amended to reduce exercise price from $0.515 to $0.33 per share.","Warrants are exercisable upon stockholder approval and expire five years thereafter; closing occurred September 18, 2024.","Roth Capital Partners acted as exclusive placement agent; 7.0% cash fee on gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209341,"accession_number":"0000950170-24-106614","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aptevo/Alligator Phase 1 ALG.APV-527 trial: 60% stable disease, 11+ month duration in breast cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 data presented at ESMO: 9 of 15 evaluable patients (60%) achieved stable disease across solid tumors.","Breast cancer patient with progressive disease at entry achieved SD for >11 months and dose-escalated twice.","Colon cancer patient with sustained SD remains on study for over 4 months.","No maximum tolerated dose identified; safety profile positive across all cohorts.","Serum concentrations consistent with dose and preclinical predictions; biomarker analyses confirm biological activity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209340,"accession_number":"0000950170-24-093356","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aptevo posts Q2 net loss $5.9M, cash $8.1M; APVO436 Phase 1b/2 trial to begin","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.9M ($1.67/sh) vs $7.9M ($53.95/sh) in Q2 2023; R&D spend down 33% to $3.6M.","Cash $8.1M at June 30; proforma $10.4M including $2.75M July direct offering, extending runway into 2025.","APVO436 Phase 1b/2 dose optimization trial for AML expected to start in Q3 2024; prior expansion showed 91% clinical benefit rate.","ALG.APV-527 solid-tumor trial >90% enrolled; data showed durable stable disease in two heavily pretreated breast cancer patients.","Max tolerated dose not yet reached for ALG.APV-527; dosing continues in cohort five."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209339,"accession_number":"0000950170-24-092865","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aptevo shareholders reject charter amendment, approve stock issuance at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1 (charter amendment) failed: FOR 929,933 / AGAINST 554,853 / ABSTAIN 24,490; required majority of outstanding shares.","Proposal 2 (stock issuance and warrant repricing) approved: FOR 306,069 / AGAINST 283,207 / ABSTAIN 10,620; 909,380 broker non-votes.","Proposal 3 (adjournment) approved: FOR 926,978 / AGAINST 561,064 / ABSTAIN 21,234.","Charter amendment defeat means Aptevo cannot implement the proposed changes without another vote.","Approved issuance relates to June 28 securities purchase agreement covering warrants with exercise price adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209338,"accession_number":"0000950170-24-079672","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Aptevo receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until Dec 23, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq Staff letter on June 25, 2024, for failure to meet minimum $1.00 bid price requirement.","Has 180 calendar days, until December 23, 2024, to regain compliance by closing at $1.00+ for 10 consecutive days.","If noncompliant by Dec 23, may be eligible for additional 180-day period if meets other listing standards and intends to cure via reverse stock split.","Failure to regain compliance could result in delisting; company will monitor and evaluate options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209337,"accession_number":"0000950170-24-079653","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Aptevo raises ~$2.75M gross in registered direct offering at $0.515/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 5,339,806 shares (or pre-funded warrants) and 10,679,612 common warrants at $0.515/share; net proceeds ~$2.3M.","Common warrants exercisable at $0.515/share upon stockholder approval, expire 5 years later.","Existing warrants from Aug 2023, Nov 2023, Apr 2024 amended to $0.515 exercise price, also subject to stockholder approval.","Proceeds for clinical development of product candidates and working capital.","Roth Capital Partners placement agent; closing July 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227328,"accession_number":"0000950170-24-071338","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aptevo stockholders elect two directors, ratify Moss Adams as auditor for 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Daniel J. Abdun-Nabi and Grady Grant III elected to board with ~470K votes for each.","Ratification of Moss Adams as independent auditor for 2024: 1,271,108 for, 232,874 against.","Second Amended and Restated 2018 Stock Incentive Plan approved: 442,849 for, 355,401 against.","Non-binding advisory vote on executive compensation approved: 436,765 for, 365,824 against.","Broker non-votes of ~704K were present on director election and incentive plan proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227327,"accession_number":"0000950170-24-055087","cik":1671584,"company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aptevo Q1 net loss $6.8M; breast cancer patient stays on ALG.APV-527 >11 months","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.8M ($9.95 per share) vs net income $2.8M ($17.38 per share) in Q1 2023.","Cash $10.3M at March 31, 2024; pro forma $14.3M after April equity raise.","Heavily pretreated breast cancer patient in ALG.APV-527 Phase 1 achieved stable disease, remains on therapy >11 months, safely transitioned to higher dose.","APVO436 Phase 1b/2 frontline AML dose optimization trial initiation expected Q2 2024; partnered with Prometrika.","R&D expenses down $0.4M to $3.8M; G&A down $0.4M to $3.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":-9.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6137066.921487603,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-05-08T23:59:59+00:00|227327"}